Alligator Bioscience

Alligator Bioscience, based in Lund, develops tumour-directed immunotherapies from its FIND antibody library and RUBY bispecific format. Mitazalimab (ADC-1013), a CD40 agonist that primes dendritic cells and T cells, was tested with modified FOLFIRINOX in the single-arm phase 1b/2 OPTIMIZE-1 trial in untreated metastatic pancreatic cancer, which met its primary endpoint with a confirmed response rate of 42.1 per cent and reported median overall survival of 14.9 months; with no control group it cannot show whether mitazalimab improves survival, and the authors plan a randomised confirmatory trial. ATOR-4066 is a Neo-X-Prime bispecific against CD40 and CEACAM5.